BioVie (OTC: BIVI) is a development-stage biotech that discovers, develops and commercializes various drug therapies in the Unites States. The company focuses on the commercialization of BIV201 for the treatment of ascites due to liver cirrhosis. It also discovers and develops broad spectrum antibiotics for gram-negative and gram-positive bacterial infections. BioVie was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie was founded in 2013 and is based in Beverly, Massachusetts. For more information, visit the company’s website at www.biovieinc.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1) access to our news aggregation and syndication servers, (2) enhanced press release services, and (3) a full array of social communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
